Annalisa Merelli,

Annalisa Merelli is a general assignment reporter at STAT. Prior to joining the newsroom, she worked as a reporter and editor at Quartz, Narratively, Global Voices, Motherland Magazine, The India Tube, and Fabrica. Her work has taken her from her hometown of Bergamo in Italy to France and India before settling in the United States. With a focus on health topics such as this article about HIV vaccine research, Annalisa provides insightful coverage of scientific developments that impact public health. She is dedicated to uncovering the truth and presenting it to her audience with clarity and precision.

Biography:  https://www.statnews.com/staff/annalisa-merelli/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • About 20% of patients produce so-called broadly neutralizing antibodies, which latch onto a wide range of strains and prevent the virus from slipping inside human cells.
  • A follow-up trial is underway at the HIV Vaccine Trials Network to see if researchers can push B cells further toward making broadly neutralizing antibodies, with results planned to be available next year.
  • A Phase 1 trial found that 35 of 36 study participants produced an initial immune response to a candidate vaccine targeted toward B cells with the potential to produce broad responses.
  • A vaccine that elicits broadly neutralizing antibodies before infection could be transformative; despite advances in HIV treatment, more than 600,000 people died of AIDS last year.
  • HIV has long stumped immunologists looking to develop an effective vaccine.
  • The last trial expected to potentially deliver a vaccine within this decade was halted.
  • Two other studies tested guiding B cells toward producing antibodies that latch onto a part of HIV known as the CD4 binding site, a region with minimal differences between strains because it's essential for infection.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

First Human Production of Elusive HIV Antibodies in Groundbreaking Vaccine Trial

First Human Production of Elusive HIV Antibodies in Groundbreaking Vaccine Trial

Broke On: Friday, 17 May 2024 Scientists have reported success in triggering the production of rare and elusive antibodies against HIV in human patients for the first time, using a novel vaccine approach. Another innovative strategy involves selectively activating rare B cells to produce broadly neutralizing antibodies. While these advancements offer hope for an eventual HIV vaccine, researchers emphasize continued exploration and building on recent successes to develop a safe and effective solution.